Gilead is a biopharmaceutical company that develops and sells medicines for HIV, hepatitis, cancer and other diseases. It last closed at $166.43 on Nov 20, down 0.06% on the day. The next earnings report for GILD is expected around Tue, Feb 9, 2027, after the close. For the quarter ended Sep 2026, GILD reported EPS of $1.94 on revenue of $8.30B, with revenue up 6.8% from a year ago. Over its last 8 reports the stock moved an average of 4.1% the session after earnings. Over the last 12 months GILD insiders bought $0 of stock on the open market and sold $108.9M, according to SEC Form 4 filings.
AI Auto Pilots
Is GILD in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GILD.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on GILDStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
GILD · as of the Nov 20 close · updated each morning
Uptrend
The stock sits between its 20 and 50 day averages. It is 14% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 54). The nearest support is the Pivot S1 at $164.74, and the nearest resistance the 20 day average at $167.29.
Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 2.7%/day
Key levels
$176.5852 week high+6.1%
$171.80Swing high (Nov 16)+3.2%
$169.18Pivot R1+1.7%
$167.49Pivot+0.6%
$167.2920 day average+0.5%
$166.43Last close
$164.74Pivot S1−1.0%
$164.00Swing low (Nov 6)−1.5%
$157.2650 day average−5.5%
$147.67100 day average−11.3%
$142.30200 day average−14.5%
$116.8852 week low−29.8%
Indicators
RSI (14)
54.42
Middle of its range
Neutral
MACD
3.21
Below its signal line
Bearish
Stochastic
26.3
Middle of its range
Neutral
ADX (14)
30.2
Trending up
Williams %R
-80.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
3.9
Oversold below −100, overbought above 100
Neutral
Rate of change
−0.3%
Change over 10 sessions
Bearish
ATR (14)
$4.54
Typical daily range, 2.7% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
Uptrend, nearing overbought
Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 5.4%/day
Key levels
$176.5852 week high+6.1%
$171.80Swing high (Nov 16)+3.2%
$169.18Pivot R1+1.7%
$167.49Pivot+0.6%
$167.2920 day average+0.5%
$166.43Last close
$164.74Pivot S1−1.0%
$164.00Swing low (Nov 6)−1.5%
$157.2650 day average−5.5%
$147.67100 day average−11.3%
$142.30200 day average−14.5%
$116.8852 week low−29.8%
Indicators
RSI (14)
66.83
Strong, overbought above 70
Neutral
MACD
8.72
Above its signal line
Bullish
Stochastic
78.4
Middle of its range
Neutral
ADX (14)
37.4
Trending up
Williams %R
-25.4
Oversold below −80, overbought above −20
Neutral
CCI (20)
131.8
Oversold below −100, overbought above 100
Overbought
Rate of change
+15.8%
Change over 10 sessions
Bullish
ATR (14)
$8.92
Typical daily range, 5.4% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for GILD
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how GILD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow GILD usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for GILDHow many large options trades hit GILD, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in GILD in the last 90 days.
From SEC Form 4 filings by GILD's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.
From the company's 10-Q filed Oct 30, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GILD is in one of them and how their past GILD trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Gilead Sciences
Gilead is a biopharmaceutical company based in Foster City, California. It develops and sells medicines for viral diseases, including HIV and hepatitis, along with cancer treatments such as a breast cancer drug and cell therapies for certain blood cancers. Its portfolio also includes an antifungal medicine and a COVID-19 treatment. Gilead sells to hospitals, clinics and other healthcare providers, largely through wholesalers, distributors and partners.